COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Acitretin Capsules

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02715960
Recruitment Status : Unknown
Verified December 2015 by Yijing He, Central South University.
Recruitment status was:  Recruiting
First Posted : March 22, 2016
Last Update Posted : March 22, 2016
Information provided by (Responsible Party):
Yijing He, Central South University

Brief Summary:
In an early clinical research, 138 patients completed the treatment of Psoriasis Vulgaris by Acitretin Capsules in 8 weeks, the results indicate 75 cases effectively (54.3%), 50 cases invalid(36.2%), 13 cases serious(9.4%). To investigate the influence of genetic factors on the curative effect and find the relationships between genetic variants and the response of Acitretin Capsules to treatment of Psoriasis Vulgaris.

Condition or disease Intervention/treatment Phase
Psoriasis Vulgaris Drug: Acitretin Capsules Phase 2

Detailed Description:
Investigators analyzed the various levels of genetic factors, including: 1.To analysis the key gene variants which associated with ADME affect the efficacy of Acitretin Capsules; 2.Direct full genetic sequencing of MHC genes, to explore the genetic variations of efficacy and side effects; 3. Direct sequencing of all exons in the gene in the patients of the response of serious and effectively, to explores the rare genetic variation may cause deterioration of treatment by Acitretin Capsules.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 500 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Acitretin Capsules
Study Start Date : December 2015
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis
Drug Information available for: Acitretin

Arm Intervention/treatment
Experimental: single-arm
intervention: open registry, non-randomized, single-arm trial. Acitretin Capsules: 2.5 per piece.
Drug: Acitretin Capsules
During The first treatment stage:10mg per day, 3 days,oral; The second stage: 20mg per day, 3 days,oral; The third stage: 30mg per day, and maintain this dose,oral.
Other Name: Tretinoin, Vitamine A Acid

Primary Outcome Measures :
  1. disease control rate [ Time Frame: 8 weeks after the first treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Diagnosed according to Classification criteria for Psoriasis vulgaris
  2. Patients aged 18 to 70 years (to the date of screening)
  3. PASI grade ≥7point
  4. Not treatment in the Topical corticosteroids, Immunosuppression, Biologicals agents or Tretinoin cream, Phototherapy nearly one months before enrolled.
  5. Total bilirubin < 1.5 x ULN, AST(SGOT)/ALT(SGPT) <2.5 x ULN if not liver metastases<5 x ULN if known liver metastases, Creatinine clearance <1.5 x ULN
  6. Understanding the whole process of the study, voluntary participation and signed the informed consent

Exclusion Criteria:

  1. Pregnant women, ready to pregnant or lactating women
  2. Have a serious heart, lung, kidney and other vital organs and endocrine system lesions and the history
  3. Patients is liver function abnormal persons (ALT above the center laboratory normal limit) or hepatitis b patient grain carriers
  4. Patients with chronic diarrhea, or peptic ulcer nearly 1 year
  5. Patients suffering from malignant tumor
  6. Patients suffering from acute and chronic infectious diseases
  7. Mental disorders, history of alcohol abuse, drug or other substance abuse
  8. Other cases which researchers believe that can not enroll

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02715960

Layout table for location contacts
Contact: Yijing He, PhD,MD +86-1587481262

Layout table for location information
China, Hunan
Xiangya Hospital Central South University Recruiting
Changsha, Hunan, China, 410008
Contact: Yijing He, MD, PhD    +86-1587481262   
Sponsors and Collaborators
Central South University
Layout table for investigator information
Principal Investigator: Xiang Chen, MD Xiangya Hospital of Central South University
Layout table for additonal information
Responsible Party: Yijing He, Associate Professor, Central South University Identifier: NCT02715960    
Other Study ID Numbers: 2016 AW/CSU/PS
First Posted: March 22, 2016    Key Record Dates
Last Update Posted: March 22, 2016
Last Verified: December 2015
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: data not entered
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases, Papulosquamous
Skin Diseases
Vitamin A
Growth Substances
Physiological Effects of Drugs
Antineoplastic Agents
Keratolytic Agents
Dermatologic Agents